Despite the G-CSF support, more than 60% of the patients developed grade 3/4 neutropenia; nevertheless, the efficacy results were promising with an ORR of 51%, including two CRs (4%) and twenty-one PRs (47%) [207]. The gene discussed is CSF3; the disease is neutropenia.